Clientelistic networks and local corruption: Evidence from Western Crete DIMITRIOS CHRISTOPOULOS

In this article, the attitudes and interaction of local political and business elites in western Crete are examined by means of an attitudinal survey, triangulated with data from in-depth interviews, conducted between July and October 1991. The data examined indicate that the endemic prevalence of clientelistic networks creates the background for corruption, although evidence of corrupt practice is not strong. In this analysis it is presumed that the attitudes and perceptions of key actors are affected by a definition of corruption that is relevant to their particular civil society alone. Data analyzed here suggest that local élite attitudes towards corruption are not perceived to affect the standards of conduct at the local level. It can also be deduced that if corruption is linked to the problems of administrative efficiency and economic development of the region, these can be related to vertical clientelistic networks with the national centre

Deletions of 17p and p53 Mutations in Preneoplastic Lesions of the Lung

Cytogenetic and p53 mutation analysis in two cases of severe dysplasia of the bronchial epithelium in lung cancer patients and p53 immunostaining in a third one are reported. The finding of both chromosomal deletions of 17p and p53 mutation indicates that these changes may take place early in the process of lung carcinogenesis

Morphologic, immunologic, and cytogenetic characteristics of secondary acute unclassifiable leukemia in Hodgkin's disease

Blast cells from five cases of secondary unclassifiable leukemia following therapy for Hodgkin's disease were studied by cytochemical, immunological and cytogenetic analyses. Cytochemical and immunological reactivity were in accordance with poorly differentiated, myeloid blasts. The four cases in which karyotype analysis was performed showed specific chromosomal abnormalities. No evidence of multiple lineage involvement was found. Problems in classifying these cases of secondary ANLL were due to the high grade of undifferentiation of the blast cells. Their low cytochemical reactivity with markers of myeloid differentiation was similar to what may be observed in patients with acute undifferentiated leukemia or with chronic myeloid leukemia in blast crisis

Cell for the in situ study of heterogeneous catalysts by transmission and fluorescence XAS spectroscopy

A simple cell, assembled with commercial parts, suitable for in situ X-ray-absorption spectroscopy measurements of heterogeneous catalysts, has been designed. The cell, light and easy to handle, allows thermal treatments of the sample under investigation up to 823 K in a reducing or oxidizing atmosphere and measurements at both high and liquid-nitrogen temperature. The cell was tested by studying the decomposition, in an oxygen flow, of ammonium metatungstate to WO3. Extended X-ray absorption fine-structure measurements of the ammonium metatungstate before and after a thermal treatment at 773 K are reported

bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.

The present study provides immunobiochemical and molecular data on the differentiation-linked expression of the bcl-2 proto-oncogene in normal and neoplastic myeloid cells. Using a recently developed monoclonal antibody (MoAb) to the bcl-2 molecule, staining of normal bone marrow myeloblasts, promyelocytes, and myelocytes, but neither monocytes nor most polymorphonuclear cells, was demonstrated. By two-color flow cytometric analysis, bcl-2 was evidenced in CD33+ and CD33+/CD34+ myeloid cells as well as in the more primitive CD33-/CD34+ population. The leukemic cell lines HL-60, KG1, GM-1, and K562 were bcl-2 positive together with 11 of 14 acute myeloid leukemias (AML) and three of three chronic myeloid leukemias (CML) in blast crises; six of seven CML were negative. Among myelodysplastic cases, augmentation of the bcl-2 positive myeloblastic compartment was found in refractory anemia with excess of blasts (RAEB) and in transformation (RAEB-t). Western blots of myeloid leukemias and control lymphocytes extracts evidenced an anti-bcl-2 immunoreactive band of the expected size (26 Kd). Moreover, the HL-60 and KG1 cell lines, both positive for the bcl-2 protein, exhibited the appropriate size bcl-2 mRNA (7.5 Kb). These findings clearly indicate that the bcl-2 gene is operative in myeloid cells and that the anti-bcl-2 MoAb identifies its product and not a cross-reactive epitope. Induction of HL-60 differentiation toward the monocytic and granulocytic pathways was accompanied by a marked decrease in bcl-2 mRNA and protein levels; bivariate flow cytometric analysis showed that the fraction becoming bcl-2 negative was in the G1 phase of the cell cycle. These data establish that the bcl-2 proto-oncogene is expressed on myeloid cells and their progenitors and is regulated in a differentiation-linked manner